================================================================================
ADMET-Î£ CASE STUDY REPORT
Generated: 2026-02-20T15:51:43.230285
================================================================================

================================================================================
COMPOUND: Aspirin
Description: Non-steroidal anti-inflammatory, COX-1/COX-2 inhibitor
SMILES: CC(=O)Oc1ccccc1C(=O)O
================================================================================

--- Physicochemical Properties ---
  MW:               180.16 Da
  LogP:             1.31
  TPSA:             63.6 A^2
  HBD / HBA:        1 / 3
  Rotatable bonds:  2
  Aromatic rings:   1
  Fsp3:             0.111
  QED:              0.55
  Lipinski:         0 violations (COMPLIANT)

--- BCS Classification ---
  Predicted class:  I (Known: I)
  Solubility:       High (logS=-2.39)
  Permeability:     High (score=1.0)
  Formulation:      Conventional immediate-release tablet; low development risk

--- pH-Dependent Solubility ---
  pH_1.2: logS = -2.39
  pH_4.5: logS = -1.91
  pH_6.8: logS = 0.21
  pH_7.4: logS = 0.81
  Ionizable: carboxylic_acid (pKa=4.2, acid)

--- Clinical Developability Score ---
  CDS:              71.5/100 (Good)
    druglikeness               65.2  (weight=0.2)
    metabolic_stability        60.0  (weight=0.2)
    safety                     65.0  (weight=0.25)
    permeability               90.0  (weight=0.15)
    physicochemical            90.0  (weight=0.2)

--- Prediction Reliability Index ---
  PRI:              0.656 (Moderate)
    applicability_domain      0.773  (weight=0.3)
    ensemble_uncertainty      0.586  (weight=0.25)
    conformal_prediction      0.864  (weight=0.2)
    model_performance         0.420  (weight=0.25)

--- Drug-Drug Interaction Assessment ---
  DDI Risk Score:   0/100 (Low)
  Substrate of:     None identified
  Inhibitor of:     None identified
  Victim drug:      No
  Perpetrator drug: No

--- Phase I Metabolite Prediction ---
  Metabolic sites:  2
    [1] Aromatic hydroxylation (CYP1A2/CYP2C9)
    [2] Ester hydrolysis (CES1/CES2)

--- Adverse Outcome Pathway Mapping ---
  AOPs triggered:   0
  AOP Risk Score:   0 (Low)

--- Beyond-Rule-of-5 / PROTAC Assessment ---
  Compound class:   ro5_compliant
  Macrocycle:        No (max ring: 6 atoms)
  Chameleonicity:   0.0
  bRo5 score:       50
  Oral risk:        Low

--- Comparative Drug Profiling ---
  Most similar:     Warfarin (Tanimoto=0.245)
  Top 5 matches:
    Warfarin              Tanimoto=0.245
    Acetaminophen         Tanimoto=0.222
    Carbamazepine         Tanimoto=0.205
    Naproxen              Tanimoto=0.205
    Propranolol           Tanimoto=0.204

================================================================================
COMPOUND: Simvastatin
Description: HMG-CoA reductase inhibitor (statin), CYP3A4 substrate
SMILES: CCC(C)(C)C(=O)OC1CC(O)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21
================================================================================

--- Physicochemical Properties ---
  MW:               420.55 Da
  LogP:             3.31
  TPSA:             93.06 A^2
  HBD / HBA:        2 / 6
  Rotatable bonds:  6
  Aromatic rings:   0
  Fsp3:             0.75
  QED:              0.641
  Lipinski:         0 violations (COMPLIANT)

--- BCS Classification ---
  Predicted class:  II (Known: II)
  Solubility:       Low (logS=-4.14)
  Permeability:     High (score=0.9)
  Formulation:      Solubility-enhancing formulation recommended: amorphous solid dispersion (PVP-VA, Soluplus), nanocrystal, or lipid-based system (SEDDS/SMEDDS)

--- pH-Dependent Solubility ---
  pH_1.2: logS = -4.14
  pH_4.5: logS = -4.14
  pH_6.8: logS = -4.14
  pH_7.4: logS = -4.14

--- Clinical Developability Score ---
  CDS:              66.8/100 (Good)
    druglikeness               70.3  (weight=0.2)
    metabolic_stability        50.0  (weight=0.2)
    safety                     65.0  (weight=0.25)
    permeability               72.0  (weight=0.15)
    physicochemical            80.0  (weight=0.2)

--- Prediction Reliability Index ---
  PRI:              0.658 (Moderate)
    applicability_domain      0.740  (weight=0.3)
    ensemble_uncertainty      0.935  (weight=0.25)
    conformal_prediction      0.488  (weight=0.2)
    model_performance         0.420  (weight=0.25)

--- Drug-Drug Interaction Assessment ---
  DDI Risk Score:   30/100 (Moderate)
  Substrate of:     CYP3A4
  Inhibitor of:     None identified
  Victim drug:      Yes
  Perpetrator drug: No
  ! Potential DDI victim via CYP3A4 -- co-administration with strong inhibitors may increase exposure

--- Phase I Metabolite Prediction ---
  Metabolic sites:  1
    [2] Ester hydrolysis (CES1/CES2)

--- Adverse Outcome Pathway Mapping ---
  AOPs triggered:   2
  AOP Risk Score:   42 (Moderate)
    AOP:34: Cholestasis [Hepatic] (confidence=0.425)
    AOP:25: Drug-induced liver injury [Hepatic] (confidence=0.3)

--- Beyond-Rule-of-5 / PROTAC Assessment ---
  Compound class:   ro5_compliant
  Macrocycle:        No (max ring: 6 atoms)
  Chameleonicity:   0.1
  bRo5 score:       50
  Oral risk:        Low

--- Comparative Drug Profiling ---
  Most similar:     Pioglitazone (Tanimoto=0.133)
  Top 5 matches:
    Pioglitazone          Tanimoto=0.133
    Ibuprofen             Tanimoto=0.108
    Warfarin              Tanimoto=0.106
    Amoxicillin           Tanimoto=0.106
    Naproxen              Tanimoto=0.103

================================================================================
COMPOUND: Cyclosporine A
Description: Macrocyclic immunosuppressant, beyond Rule-of-5
SMILES: CCC1NC(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)CC)N(C)C(=O)CN(C)C(=O)C(C(C)C)N(C)C1=O
================================================================================

--- Physicochemical Properties ---
  MW:               1159.61 Da
  LogP:             4.4
  TPSA:             249.7 A^2
  HBD / HBA:        4 / 11
  Rotatable bonds:  16
  Aromatic rings:   0
  Fsp3:             0.803
  QED:              0.158
  Lipinski:         2 violations (NON-COMPLIANT)

--- BCS Classification ---
  Predicted class:  II (Known: IV)
  Solubility:       Low (logS=-8.75)
  Permeability:     High (score=0.75)
  Formulation:      Solubility-enhancing formulation recommended: amorphous solid dispersion (PVP-VA, Soluplus), nanocrystal, or lipid-based system (SEDDS/SMEDDS)

--- pH-Dependent Solubility ---
  pH_1.2: logS = -8.75
  pH_4.5: logS = -8.75
  pH_6.8: logS = -8.75
  pH_7.4: logS = -8.75

--- Clinical Developability Score ---
  CDS:              31.9/100 (Poor)
    druglikeness                8.7  (weight=0.2)
    metabolic_stability        30.0  (weight=0.2)
    safety                     59.0  (weight=0.25)
    permeability               45.0  (weight=0.15)
    physicochemical            10.0  (weight=0.2)

--- Prediction Reliability Index ---
  PRI:              0.514 (Moderate)
    applicability_domain      0.486  (weight=0.3)
    ensemble_uncertainty      0.509  (weight=0.25)
    conformal_prediction      0.679  (weight=0.2)
    model_performance         0.420  (weight=0.25)

--- Drug-Drug Interaction Assessment ---
  DDI Risk Score:   15/100 (Low)
  Substrate of:     None identified
  Inhibitor of:     None identified
  Victim drug:      No
  Perpetrator drug: No

--- Phase I Metabolite Prediction ---
  Metabolic sites:  2
    [1] N-demethylation (CYP3A4/CYP2D6)
    [2] N-oxidation (CYP3A4/FMO3)

--- Adverse Outcome Pathway Mapping ---
  AOPs triggered:   2
  AOP Risk Score:   42 (Moderate)
    AOP:34: Cholestasis [Hepatic] (confidence=0.425)
    AOP:25: Drug-induced liver injury [Hepatic] (confidence=0.3)

--- Beyond-Rule-of-5 / PROTAC Assessment ---
  Compound class:   bro5_large
  Macrocycle:        Yes (max ring: 30 atoms)
  Chameleonicity:   0.9
  bRo5 score:       30
  Oral risk:        High

--- Comparative Drug Profiling ---
  Most similar:     Pioglitazone (Tanimoto=0.103)
  Top 5 matches:
    Pioglitazone          Tanimoto=0.103
    Amoxicillin           Tanimoto=0.091
    Ibuprofen             Tanimoto=0.089
    Losartan              Tanimoto=0.086
    Amlodipine            Tanimoto=0.078

================================================================================
COMPOUND: ARV-110
Description: PROTAC degrader targeting androgen receptor (Arvinas)
SMILES: CC(C)c1cc(NC(=O)COc2ccc(-c3cnc4cc(F)c(OCC5CCN(CC6CC(=O)NC(=O)C6)C5)cc4n3)cc2)ccc1F
================================================================================

--- Physicochemical Properties ---
  MW:               657.72 Da
  LogP:             5.47
  TPSA:             122.75 A^2
  HBD / HBA:        2 / 8
  Rotatable bonds:  11
  Aromatic rings:   4
  Fsp3:             0.361
  QED:              0.204
  Lipinski:         2 violations (NON-COMPLIANT)

--- BCS Classification ---
  Predicted class:  II (Known: IV)
  Solubility:       Low (logS=-7.13)
  Permeability:     High (score=0.75)
  Formulation:      Solubility-enhancing formulation recommended: amorphous solid dispersion (PVP-VA, Soluplus), nanocrystal, or lipid-based system (SEDDS/SMEDDS)

--- pH-Dependent Solubility ---
  pH_1.2: logS = 3.67
  pH_4.5: logS = -2.85
  pH_6.8: logS = -5.89
  pH_7.4: logS = -6.43
  Ionizable: tertiary_amine (pKa=8.0, base)
  Ionizable: pyridine (pKa=5.2, base)

--- Clinical Developability Score ---
  CDS:              21.2/100 (Poor)
    druglikeness               11.2  (weight=0.2)
    metabolic_stability         5.0  (weight=0.2)
    safety                     35.0  (weight=0.25)
    permeability               55.0  (weight=0.15)
    physicochemical            10.0  (weight=0.2)

--- Prediction Reliability Index ---
  PRI:              0.643 (Moderate)
    applicability_domain      0.618  (weight=0.3)
    ensemble_uncertainty      0.813  (weight=0.25)
    conformal_prediction      0.747  (weight=0.2)
    model_performance         0.420  (weight=0.25)

--- Drug-Drug Interaction Assessment ---
  DDI Risk Score:   35/100 (Moderate)
  Substrate of:     None identified
  Inhibitor of:     CYP2D6
  Victim drug:      No
  Perpetrator drug: Yes
  ! Potential CYP2D6 inhibitor -- may increase exposure of CYP2D6 substrates

--- Phase I Metabolite Prediction ---
  Metabolic sites:  2
    [1] Aromatic hydroxylation (CYP1A2/CYP2C9)
    [2] N-oxidation (CYP3A4/FMO3)

--- Adverse Outcome Pathway Mapping ---
  AOPs triggered:   2
  AOP Risk Score:   42 (Moderate)
    AOP:34: Cholestasis [Hepatic] (confidence=0.425)
    AOP:25: Drug-induced liver injury [Hepatic] (confidence=0.3)

--- Beyond-Rule-of-5 / PROTAC Assessment ---
  Compound class:   bro5_moderate
  Macrocycle:        No (max ring: 6 atoms)
  Chameleonicity:   0.2
  bRo5 score:       50
  Oral risk:        Moderate
  PROTAC:           Yes (E3=glutarimide_crbn)
    + Multiple rings provide structural rigidity

--- Comparative Drug Profiling ---
  Most similar:     Imatinib (Tanimoto=0.194)
  Top 5 matches:
    Imatinib              Tanimoto=0.194
    Pioglitazone          Tanimoto=0.185
    Metoprolol            Tanimoto=0.167
    Naproxen              Tanimoto=0.155
    Omeprazole            Tanimoto=0.149